Expression of p130cas, E-cadherin and β-Catenin and their correlation with clinicopathological parameters in non-small cell lung cancer: P130cas over-expression predicts poor prognosis

Folia Histochemica et Cytobiologica

Volumn 50, Issue 3, 2012, Pages 392-397

  Miao, Yuan ^a   Li, Ai Lin ^a   Wang, Liang ^a   Fan, Chui Feng ^a   Zhang, Xiu Peng ^a   Xu, Hong Tao ^a   Han, Yang ^a   Liu, Yang ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

E cadherin; Non small cell lung cancer; p130cas; Prognosis; catenin

Indexed keywords

BETA CATENIN; CRK ASSOCIATED SUBSTRATE PROTEIN; UVOMORULIN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MOLECULAR PATHOLOGY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 84867797671     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0053     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61:91-112.
3. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669-692.
4. Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67:1025-1048.
5. Reynolds AB, Roesel DJ, Kanner SB, Parsons JT. Transformation- specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol. 1989;9:629-638.
6. Kanner SB, Reynolds AB, Parsons JT. Tyrosine phosphorylation of a 120-kilodalton pp60src substrate upon epidermal growth factor and platelet-derived growth factor receptor stimulation and in polyomavirus middle-T-antigen-transformed cells. Mol Cell Biol. 1991;11:713-720.
7. Sakai R, Iwamatsu A, Hirano N et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. Embo J. 1994;13:3748-3756.
8. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer. 2010;10:858-870.
9. Defilippi P, Di Stefano P, Cabodi S. P130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006;16:257-263.
10. Klemke RL, Leng J, Molander R et al. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol. 1998;140:961-972.
11. Brabek J, Constancio SS, Siesser PF et al. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol Cancer Res. 2005;3:307-315.
12. Cabodi S, Tinnirello A, Di Stefano P et al. P130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006;66:4672-4680.
13. Dorssers LC, Grebenchtchikov N, Brinkman A et al. Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Clin Chem. 2004;50:1445-1447.
14. Deng B, Huang W, Tan QY et al. Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum. Mol Diagn Ther. 2011;15:31-40.
15. Guo C, Liu QG, Yang W, Zhang ZL, Yao YM. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008;7:490-496.
16. Nick AM, Stone RL, Armaiz-Pena G et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011;103:1596-1612.
17. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151-166.
18. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27:6920-6929.
19. Tikhmyanova N, Golemis EA. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One. 2011;6:e22102.
20. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
21. Goldstraw P. Updated staging system for lung cancer. Surg Oncol Clin N Am. 2011;20:655-666.
22. Miao Y, Liu N, Zhang Y et al. P120ctn isoform 1 expression significantly correlates with abnormal expression of E-cadherin and poor survival of lung cancer patients. Med Oncol. 2010;27:880-886.
23. Xu HT, Wang L, Lin D et al. Abnormal â-Catenin and Reduced Axin Expression are Associated with Poor Differentiation and Progression in Non-Small Cell Lung Cancer. Am J Clin Pathol. 2006;125:534-541.
24. Fromont G, Vallancien G, Validire P, Levillain P, Cussenot O. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate. 2007;67:268-273.